48-wk resistance data comparing GW433908 boosted & unboosted with nelfinavir

Boston (Feb. 11, 2003) Forty-eight-week data were presented here today from two Phase III studies (NEAT and SOLO) of treatment-nave patients with HIV infection, evaluating the resistance profile of the investigational protease inhibitor (PI) GW433908 (908) dosed twice a day (BID) or 908 boosted with the PI ritonavir (908/r) dosed once a day (QD) compared to the PI nelfinavir (NFV) BID. The medications in both studies were administered as part of combination therapy that also included 300 mg abacavir (ABC) BID and 150 mg lamivudine (3TC) BID. ABC and 3TC are nucleoside reverse transcriptase inhibitors (NRTIs).

908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX). In the SOLO study, no patients (0 percent) in the 908/r arm, out of 32 subjects experiencing virologic failure or with ongoing viral replication, had detectable primary or secondary PI mutations. In contrast, 27 of 54 patients (50 percent) in the NFV arm developed primary or secondary PI mutations. The clinical relevance of the resistance data is currently under evaluation.

In the NEAT study, 5 of 29 patients (17 percent) who experienced treatment failure in the unboosted 908 arm had mutations characteristic of APV resistance. NFV-selected mutations were observed in 7 of 26 patients (27 percent) who experienced virologic failure in the nelfinavir arm.

In the NEAT study, mutations selected by 908 were consistent with the spectrum of mutations selected by APV. Mutations detected in patients taking unboosted 908 included I54L/M, M46I and V32I+I47V. Mutations observed with other PIs (D30N, I54V, V82A/T/S, L90M) were not detected among patients taking unboosted 908.

In the SOLO study, there was a statistically significant difference between 908/r QD and NFV BID in the incidence of treatment emergent mutations selected by either the study PI (P<0.001) or the NRTIs ABC and

Contact: Amy Kling
Public Communications Inc.

Page: 1 2 3

Related biology news :

1. Master of antimalarial resistance
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Evolvability could be a driving force in drug resistance
4. Insecticide resistance: A constraint on evolutionary change
5. New drug shows promise against Gleevec resistance in mice
6. New milestones on the path to conquering HIV drug resistance (AIDS)
7. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
8. Antibiotic resistance risk from triclosan questioned
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Researchers string together players in pesticide resistance orchestra
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:

(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/11/2015)... 11, 2015   MedNet Solutions , an innovative SaaS-based ... research, is pleased to announce that it will be a ... event, to be held November 17-19 in ... live demonstrations of iMedNet , MedNet,s easy-to-use, ... iMedNet has been able to deliver time and cost ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... ... November 30, 2015 , ... ... join physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for ... held in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... 2015 Partnership includes an MPP ... for the u niversity , s ... treatment s cale - up through ... Africa , where licensees based anywhere in the world will have ... --> Africa , where licensees based anywhere in the world ...
Breaking Biology Technology:
Cached News: